We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
(+13%)
Cap. Flow
+$64.9M
Cap. Flow
% of AUM
3.27%
Top 10 Holdings %
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65
Avg Time Held Equity + Options
4.7
quarters
Top 10 Avg Time Held Equity + Options
5.1
quarters
Top 20 Avg Time Held Equity + Options
6.3
quarters
Avg Time Held Equity only
4.9
quarters
Top 10 Avg Time Held Equity only
5.1
quarters
Top 20 Avg Time Held Equity only
6.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$46.6M |
| 2 |
Puma Biotechnology
PBYI
|
+$41M |
| 3 |
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
|
+$35.9M |
| 4 |
CORI
Corium International, Inc.
CORI
|
+$19M |
| 5 |
Intuitive Surgical
ISRG
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aclaris Therapeutics
ACRS
|
+$37.6M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$22.2M |
| 3 |
NEVRO CORP.
NVRO
|
+$20.4M |
| 4 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$13.3M |
| 5 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$12.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.26% |
| 2 | Miscellaneous | 3.45% |
| 3 | Consumer Staples | 0.19% |
| 4 | Consumer Discretionary | 0.06% |
| 5 | Energy | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Edwards Lifesciences
EW
$49.8B
| $719K | 0.04% |
+18,264
| New | +$667K |
2017 Q2
0 quarters
|
|
102
Incyte
INCY
$22.6B
| $707K | 0.04% |
5,619
| – | – |
2016 Q3
3 quarters
|
|
|
ZSAN
103
DELISTED
Zosano Pharma Corporation
ZSAN
| $705K | 0.04% |
714
| – | – |
2017 Q1
1 quarter
|
|
104
Stellantis
STLA
$12.7B
| $659K | 0.03% |
62,248
| – | – |
2015 Q2
8 quarters
|
|
|
HRC
105
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $631K | 0.03% |
7,930
| – | – |
2016 Q3
3 quarters
|
|
|
ACOR
106
DELISTED
Acorda Therapeutics
ACOR
| $626K | 0.03% |
+265
| New | +$525K |
2017 Q2
0 quarters
|
|
107
Centene
CNC
$33.1B
| $617K | 0.03% |
15,452
| – | – |
2017 Q1
1 quarter
|
|
|
AKAO
108
DELISTED
Achaogen Inc
AKAO
| $599K | 0.03% |
27,551
+4,055
| +17% | +$92.6K |
2017 Q1
1 quarter
|
|
109
Vanda Pharmaceuticals
VNDA
$275M
| $591K | 0.03% |
36,232
| – | – |
2017 Q1
1 quarter
|
|
110
Molina Healthcare
MOH
$10.7B
| $563K | 0.03% |
+8,140
| New | +$499K |
2017 Q2
0 quarters
|
|
111
Ferrari
RACE
$68.3B
| $533K | 0.03% |
6,200
| – | – |
2016 Q1
5 quarters
|
|
112
Protara Therapeutics
TARA
$164M
| $518K | 0.03% |
8,353
| – | – |
2014 Q4
10 quarters
|
|
113
Icon
ICLR
$12.7B
| $507K | 0.03% |
+5,187
| New | +$459K |
2017 Q2
0 quarters
|
|
|
SYNH
114
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $499K | 0.03% |
+8,532
| New | +$443K |
2017 Q2
0 quarters
|
|
115
DELISTED
Cidara Therapeutics
CDTX
| $465K | 0.02% |
3,106
-38,212
| -92% | -$5.28M |
2015 Q2
8 quarters
|
|
|
DPLO
116
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $454K | 0.02% |
+30,658
| New | +$511K |
2017 Q2
0 quarters
|
|
|
PTLA
117
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $442K | 0.02% |
7,870
-50,000
| -86% | -$2M |
2017 Q1
1 quarter
|
|
118
Voyager Therapeutics
VYGR
$140M
| $310K | 0.02% |
+34,604
| New | +$348K |
2017 Q2
0 quarters
|
|
119
DELISTED
Cutera, Inc.
CUTR
| $310K | 0.02% |
11,981
-12,000
| -50% | -$262K |
2017 Q1
1 quarter
|
|
120
Grace Therapeutics
GRCE
$42.5M
| $247K | 0.01% |
3,887
| – | – |
2013 Q3
15 quarters
|
|
|
ONSIW
121
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
| $80K | ﹤0.01% |
462,500
| – | – |
2016 Q2
4 quarters
|
|
|
ONSIZ
122
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
| $42K | ﹤0.01% |
462,500
| – | – |
2016 Q2
4 quarters
|
|
123
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $15K | ﹤0.01% |
3,476
| – | – |
2016 Q1
5 quarters
|
|
124
AbbVie
ABBV
$497B
| – | – |
-380
| Closed | -$25K | – |
|
125
Abbott
ABT
$176B
| – | – |
-415
| Closed | -$18K | – |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2017 Portfolio in Review
As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Perceptive Advisors deployed $64.9M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.
- Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
- Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
- Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
- Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
- Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
- Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
- Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.
Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.